Preferences help
enabled [disable] Abstract
Number of results
2009 | 7 | 4 | 237-247
Article title

Znaczenie kliniczne ekspresji neuropiliny-1 u chorych na raka jajnika

Title variants
Clinical signifi cance of neuropilin-1 expression in patients with ovarian cancer
Languages of publication
Background: Angiogenesis is a key process in the development of a malignant tumor, enabling both growth of primary lesion and spread of metastases. Most potent stimulators of normal and pathological angiogenesis are proteins of the vascular endothelial growth factor (VEGF) family. Regulation of angiogenesis process is also mediated by neuropilin- 1 (NP-1), as coreceptor VEGFR-2. NP-1 plays a crucial role controlling both normal angiogenesis during embryonal development and pathological angiogenesis in malignant tumors. The aim of this paper was to assess NP-1 expression in ovarian cancer and to analyze correlations between NP-1 expression and selected clinical-pathological factors in a group of ovarian cancer patients. Material and method: Analyzed was the relative level of NP-1 in 168 surgical specimens collected during surgical procedures performed at the Department of Oncologic Gynecology of Medical University in Gdańsk. Tissue samples included: 32 healthy tissues, 42 benign tumors, 10 borderline tumors, 76 ovarian cancers, 8 metastatic tumors. Relative NP-1 level was assessed using Western blotting technology. Results: Overexpression of NP-1 was seen significantly more often in early clinical stages of ovarian cancer (p=0.01), in cancers other than serous (p=0.04) and in patients with peritoneal exudate (p=0.03). Log-rank test did not reveal any significant correlation between NP-1 expression and favorable response to chemotherapy, disease-free survival or total survival time. Conclusions. Elevated NP-1 level seen in initial clinical stages of ovarian cancer may indicate crucial role of neoangiogenesis in the early phase of tumor development.
Physical description
  • Katedra i Klinika Ginekologii Onkologicznej Gdańskiego Uniwersytetu Medycznego, ul. Kliniczna 1 A, 80-402 Gdańsk, tel.: 58 349 34 41. Kierownik Kliniki: dr n. med. Dariusz Wydra
  • Wydział Biochemii Uniwersytetu Gdańskiego. Kierownik: prof. dr hab. Barbara Lipińska
  • Katedra i Klinika Ginekologii i Ginekologii Onkologicznej Gdańskiego Uniwersytetu Medycznego. Kierownik Kliniki: dr n. med. Dariusz Wydra
  • Wydział Biochemii Uniwersytetu Gdańskiego. Kierownik: prof. dr hab. Barbara Lipińska
  • Katedra i Klinika Ginekologii i Ginekologii Onkologicznej Gdańskiego Uniwersytetu Medycznego. Kierownik Kliniki: dr n. med. Dariusz Wydra
  • Katedra i Klinika Ginekologii i Ginekologii Onkologicznej Gdańskiego Uniwersytetu Medycznego. Kierownik Kliniki: dr n. med. Dariusz Wydra
  • 1. Ozols R. F.: Challenges for chemotherapy in ovarian cancer. Ann. Oncol. 2006; 17 supl. 5: v181-v187.
  • 2. Folkman J.: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285: 1182-1186.
  • 3. Ferrara N.: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9 supl. 1: 2-10.
  • 4. Hoeben A., Landuyt B., Highley M. S. i wsp.: Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 2004; 56: 549-580.
  • 5. Shibuya M., Claesson-Welsh L.: Signal transduction by VEGF receptors in regulation of angiogenesis and lymp-hangiogenesis. Exp. Cell Res. 2006; 312: 549-560.
  • 6. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K.: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000; 60: 203-212.
  • 7. Oh H., Takagi H., Otani A. i wsp.: Selective induction of neu-ropilin-1 by vascular endothelial growth factor (VEGF):a mechanism contributing to VEGF-induced angiogenesis. Proc. Natl Acad. Sci. USA 2002; 99: 383-388.
  • 8. Hucz J., Szala S.: Receptor VEGFR-2 - cel terapii kierowanej w chorobach nowotworowych. Współcz. Onkol. 2006: 10: 506-514.
  • 9. Petrova T. V, Makinen T., Alitalo K.: Signaling via vascular endothelial growth factor receptors. Exp. Cell Res. 1999; 253: 117-130.
  • 10. Miao H. Q., Klagsbrun M.: Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev. 2000; 19: 29-37.
  • 11. Stephenson J. M., Banerjee S., Saxena N. K. i wsp.: Neuro-pilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int. J. Cancer 2002; 101: 409-414.
  • 12. Kawakami T., Tokunaga T., Hatanaka H. i wsp.: Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002; 95: 2196-2201.
  • 13. Vanveldhuizen P. J., Zulfiqar M., Banerjee S. i wsp.: Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol. Rep. 2003; 10: 1067-1071.
  • 14. Parikh A. A., Liu W B., Fan F. i wsp.: Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 2003; 98: 720-729.
  • 15. Osada H., Tokunaga T., Nishi M. i wsp.: Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma. Anticancer Res. 2004; 24: 547-552.
  • 16. Parikh A. A., Fan F., Liu W B. i wsp.: Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am. J. Pathol. 2004; 164: 2139-2151.
  • 17. Ochiumi T., Kitadai Y., Tanaka S. i wsp.: Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer. Int. J. Oncol. 2006; 29: 105-116.
  • 18. Kreuter M., Woelke K., Bieker R. i wsp.: Correlation of neu-ropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 2006; 20: 1950-1954.
  • 19. Ghosh S., Sullivan C. A., Zerkowski M. P. i wsp.: High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum. Pathol. 2008; 39: 1835-1843.
  • 20. Kamiya T., Kawakami T., Abe Y. i wsp.: The preserved expression of neuropilin (NRP) 1 contributes to a better prognosis in colon cancer. Oncol. Rep. 2006; 15: 369-373.
  • 21. Wey J.S., Gray M.J., Fan F. i wsp.: Overexpression of neuro-pilin-1 promotes constitutive MAPK signalling and chemore-sistance in pancreatic cancer cells. Br. J. Cancer 2005; 93: 233-241.
  • 22. Hall G.H., Turnbull L.W, Bedford K. i wsp.: Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours. Int. J. Oncol. 2005; 27: 1283-1288.
  • 23. Stoeck A., Schlich S., Issa Y. i wsp.: L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesotheli-al cells. Cancer Lett. 2006; 239: 212-226.
  • 24. Osada R., Horiuchi A., Kikuchi N. i wsp.: Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum. Pathol. 2006; 37: 1414-1425.
  • 25. Baba T., Kariya M., Higuchi T. i wsp.: Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol. Oncol. 2007; 105: 703-711.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.